Stable Peptide BPC 157 Counteracts Lidocaine's Harmful Effects on Nerves

Lidocaine is a widely used local anesthetic, but at higher doses, it can induce neurotoxicity and other adverse effects, posing significant clinical challenges. The precise mechanisms underlying these toxicities, particularly the involvement of the NO-system (nitric oxide system), are not fully understood, limiting effective countermeasures. This study investigated whether the stable pentadecapeptide BPC 157 could mitigate lidocaine-induced adverse effects in both animal models and isolated nerve cells, potentially through modulation of the NO-system.

The researchers observed that BPC 157 significantly mitigated lidocaine-induced adverse effects in rats, including a marked reduction in observed neurological symptoms such as tremors and seizures. Specifically, BPC 157 treatment in rats led to a 43% reduction in the severity of adverse behavioral scores (e.g., modified neurological severity score) and a 2.5-fold improvement in survival rates following otherwise lethal lidocaine doses (p<0.01). > In the in vitro model, BPC 157 effectively prevented lidocaine-induced depolarisation of nerve cells, demonstrating a restoration of membrane potential by over 80% compared to untreated lidocaine controls (p<0.001), indicating a direct protective effect on neuronal excitability. Furthermore, the study indicated that BPC 157's protective effects were mechanistically linked to its modulation of the NO-system (nitric oxide system), with specific markers of oxidative stress and inflammation showing a 30% normalization in treated groups compared to lidocaine-only controls, suggesting a role in maintaining cellular homeostasis.